[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 16 of about 16
1. Raguz S, Randle RA, Sharpe ER, Foekens JA, Sieuwerts AM, Meijer-van Gelder ME, Melo JV, Higgins CF, Yagüe E: Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer. Int J Cancer; 2008 Mar 1;122(5):1058-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer.
  • Multidrug resistance, the phenomenon by which cells treated with a drug become resistant to the cytotoxic effect of a variety of other structurally and functionally unrelated drugs, is often associated with the expression of P-glycoprotein, an efflux membrane pump coded by the MDR1 (ABCB1) gene.
  • We have previously determined that the USP is activated in some drug-resistant cell lines, in primary breast tumors and in metastatic epithelial cells isolated from the lymph nodes of breast cancer patients.
  • In this study, we report the cloning and characterization of the MDR1 USP and studied its association with chemotherapy response in breast cancer patients.
  • Deletion analysis indicated that a nearby endogenous retroviral long terminal repeat is not responsible for promoter activation, and that the region within the first 400 nucleotides upstream from the transcription start point contained all the elements necessary for promoter activity in drug-resistant cells.
  • We identified an element recognized by the transcription factor NF-IL6 (activated upon interleukin-6 exposure) which is necessary for promoter activity in drug-resistant cells and plays a role in the activation of the promoter in response to interleukin-6 in breast cancer MCF-7 cells.
  • Although transcripts from this promoter are associated with translating polyribosomes, their low abundance makes the amount of synthesized P-glycoprotein insufficient to affect the response to first-line chemotherapy in patients with advanced breast cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / genetics. Drug Resistance, Multiple / genetics. P-Glycoprotein / genetics. Promoter Regions, Genetic / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17955490.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / P-Glycoprotein; 0 / RNA, Messenger
  •  go-up   go-down


2. Tarantal AF, O'Rourke JP, Case SS, Newbound GC, Li J, Lee CI, Baskin CR, Kohn DB, Bunnell BA: Rhesus monkey model for fetal gene transfer: studies with retroviral- based vector systems. Mol Ther; 2001 Feb;3(2):128-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many life-threatening conditions that can be diagnosed early in gestation may be treatable in utero using gene therapy.
  • Included in these studies were Moloney murine leukemia virus (MLV)-based amphotropic retrovirus, vesicular stomatitis virus-G (VSV-G) pseudotyped MLV, and a VSV-G pseudotyped HIV-1-based vector, all expressing the enhanced green fluorescent protein (EGFP) as a reporter gene and driven by a cytomegalovirus-immediate early promoter (N = 16).
  • Fetuses were monitored sonographically, specimens were collected prenatally and postnatally, and tissue harvests were performed at birth or 3 or 6 months postnatal age (3-10 months post-gene transfer).
  • PCR analyses demonstrated that transduced cells were present at approximately 1.2% in peripheral blood mononuclear cells from fetuses administered amphotropic MLV, <0.5% in fetuses receiving MLV/VSV-G, and approximately 4.2% for the lentiviral vector, which decreased to 2% at birth.
  • Hematopoietic progenitors showed that overall (mean of all time points assessed), approximately 25% of the collected colonies were positive for the EGFP transgene with the lentiviral vector, which was significantly greater than results achieved with the MLV-based vector systems (4-9%; P < or = 0.001-0.016).
  • At necropsy, 0.001-10% of the total genomic DNA was positive for EGFP in most tissues for all groups.
  • EGFP-positive fluorescent cells were found in cell suspensions of thymus, liver, spleen, lymph nodes, cerebral cortex, and bone marrow (0.5-6%).
  • (1) healthy infants expressing vector sequences up to 10 months post-gene transfer, (2) fetal primate administration of retroviral vectors results in gene transfer to multiple organ systems, (3) the highest level of gene transfer to hematopoietic progenitors was observed with the lentiviral vector system, and (4) there was no evidence of transplacental transfer of vector sequences into the dams.
  • [MeSH-major] Gene Transfer Techniques. Genetic Therapy / methods. Genetic Vectors. Macaca mulatta / genetics. Membrane Glycoproteins. Retroviridae / genetics
  • [MeSH-minor] Animals. Azacitidine / pharmacology. Cytomegalovirus / genetics. Dose-Response Relationship, Drug. Female. Flow Cytometry. Genes, Reporter. Green Fluorescent Proteins. HIV-1 / genetics. Humans. Lentivirus / genetics. Leukocytes, Mononuclear / metabolism. Luminescent Proteins / genetics. Male. Models, Genetic. Moloney murine leukemia virus / genetics. Polymerase Chain Reaction. Promoter Regions, Genetic. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Tissue Distribution. Viral Envelope Proteins / genetics

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Mol Ther. 2001 Feb;3(2):274-5 [11237685.001]
  • (PMID = 11237669.001).
  • [ISSN] 1525-0016
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI32266; United States / NHLBI NIH HHS / HL / HL55175; United States / NCRR NIH HHS / RR / RR00169
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / G protein, vesicular stomatitis virus; 0 / Luminescent Proteins; 0 / Membrane Glycoproteins; 0 / Viral Envelope Proteins; 147336-22-9 / Green Fluorescent Proteins; M801H13NRU / Azacitidine
  •  go-up   go-down


3. Wataya H, Asou H, Maruyama R, Okamoto T, Suemitsu R, Ichinose Y: [A case of adenocarcinoma of the lung significantly responding to TS-1 plus cisplatin combination chemotherapy]. Gan To Kagaku Ryoho; 2006 Apr;33(4):501-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adenocarcinoma of the lung significantly responding to TS-1 plus cisplatin combination chemotherapy].
  • Chest radiograph and computed tomography revealed a huge mass invading the mediastinum, enlargement of right hilar and cardiophrenic lymph nodes and nodules in right lower lobe and left upper lobe.
  • Multiple space occupying regions in the liver were also observed.
  • Cytology for exfoliated sputum revealed adenocarcinoma, so he was diagnosed with advanced lung cancer (clinical stage T 4 N 2 M 1, stage IV).
  • He was enrolled in a clinical phase II study, and received combination chemotherapy with TS-1 and cisplatin.
  • The patient then received 6 cycles of chemotherapy,and yielded a partial response (87% decrease in size determined by RECIST criteria version 2. 0).
  • Grade 2 leukopenia and neutropenia were observed, and non-hematologic toxicities were also mild.
  • The disease progressed after the end of chemotherapy, and he was given 5 regimens of chemotherapy, including gefitinib.
  • Time to progression of his disease for combination chemotherapy using TS-1 and cisplatin chemotherapy was 240 days.
  • Survival time was 709 days.
  • This combination chemotherapy was effective in the present case, and might prolong survival.
  • We think it is valuable to confirm the efficacy of TS-1 and cisplatin combination chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy
  • [MeSH-minor] Aged. Brain Neoplasms / secondary. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Humans. Leukopenia / chemically induced. Male. Neutropenia / chemically induced. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612161.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; Clinical Trial, Phase II; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Dieckmann K, Pötter R, Hofmann J, Heinzl H, Wagner W, Schellong G, Pediatric Cooperative Hodgkin Disease Study Group of the GPOH: Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90. Int J Radiat Oncol Biol Phys; 2003 Jul 1;56(3):644-52
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.
  • PURPOSE: The identification of risk factors is required for risk-adapted treatment strategies in the treatment of Hodgkin's disease.
  • To assess the influence of bulky disease at diagnosis as compared with other risk factors on event-free survival (EFS) in pediatric Hodgkin's disease such as stage, B-symptoms, number of involved lymph node regions, histology, and remission status after chemotherapy, we analyzed the outcome of 552 patients treated with a risk-adapted treatment strategy consisting of OPPA(OEPA)/COPP (vincristine, procarbazine, etoposide, prednisone, adriamycin, cyclophosphamide) and involved-field radiotherapy.
  • Patients were stratified into three treatment groups (TGs) for early, intermediate, and advanced stage.
  • All patients received induction chemotherapy (CT) with two cycles of OEPA for boys and two cycles of OPPA for girls.
  • Chemotherapy was followed by involved-field radiotherapy.
  • The radiation field, which was prescribed by the study center, was treated with a dose of 25 Gy/25 Gy/20 Gy (TG1/TG2/TG3), and in case of insufficient remission with a local boost of 5 Gy to 10 Gy.
  • The following prognostic factors were analyzed with regard to their impact on EFS: bulky disease, mediastinal tumor, number of involved lymph node regions, histology, treatment group, B-symptoms, sex, age, and remission status after chemotherapy.
  • RESULTS: Significant univariate predictive factors for the EES were: nodular sclerosis type 2 (NS2) histology (relative risk [RR] 3.43; p = 0.0002), presence of B-symptoms (RR 2.70; p = 0.0014), number of involved regions (1.55; p = 0.019), and treatment groups (RR 1.33; p = 0.017).
  • In the multiple regression model, only NS2 and B-symptoms remained strong predictive factors.
  • The remission status after chemotherapy did not correlate with EFS (p = 0.66).
  • CONCLUSION: Treatment strategies in Hodgkin's disease have an impact on different risk factors.
  • In the risk-adapted treatment strategy of the HD-90 study, tumor burden indicated as bulky disease or as number of involved lymph nodes loses its importance, whereas NS2 histology and B-symptoms have a major impact on treatment outcome.
  • Bulky disease at diagnosis might require higher radiation doses only in case of insufficient remission.
  • [MeSH-minor] Adolescent. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Lymphatic Metastasis. Male. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / radiotherapy. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Proportional Hazards Models. Radiotherapy Dosage. Recurrence. Remission Induction. Retrospective Studies. Risk Factors. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12788169.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; COPP protocol; DVPP protocol
  •  go-up   go-down


5. Nohara T, Sakai A, Fuse H, Imamura Y: [Metastatic malignant melanoma of the urinary bladder: a case report]. Nihon Hinyokika Gakkai Zasshi; 2009 Nov;100(7):707-11
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic malignant melanoma of the urinary bladder: a case report].
  • A 62-year-old male underwent resection of malignant melanoma of left breast skin in 2006.
  • In 2007, he underwent lymph node dissection and chemotherapy (DAV-feron therapy) for left axillary lymph nodes metastasis.
  • Two non-papillary bladder tumors were detedted on cystoscopy and CT/ MRI showed multiple lymph node swelling, including left inguinal, paraaortic, and right cervical regions.
  • As malignant melanoma cells were found on urinary cytology, a diagnosis of metastatic malignant melanoma of the urinary bladder was made.
  • It was thought that tumor resection would not contribute to prognostic improvement because of multiple lymph node metastases.
  • The patient is currently receiving chemotherapy.
  • This is the eleventh case of metastatic malignant melanoma of the urinary bladder to be reported in the Japanese literature.
  • There have been no previous reports of cases in which urinary cytology was positive for malignant melanoma cells.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy. Melanoma / secondary. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Dacarbazine / administration & dosage. Humans. Interferon-beta / administration & dosage. Lymphatic Metastasis. Male. Middle Aged. Nimustine / administration & dosage. Skin Neoplasms / pathology. Skin Neoplasms / therapy. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999137.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0S726V972K / Nimustine; 5J49Q6B70F / Vincristine; 77238-31-4 / Interferon-beta; 7GR28W0FJI / Dacarbazine; DAV protocol
  • [Number-of-references] 9
  •  go-up   go-down


6. Tu DG, Yao WJ, Chang TW, Chiu NT, Chen YH: Flare phenomenon in positron emission tomography in a case of breast cancer--a pitfall of positron emission tomography imaging interpretation. Clin Imaging; 2009 Nov-Dec;33(6):468-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flare phenomenon in positron emission tomography in a case of breast cancer--a pitfall of positron emission tomography imaging interpretation.
  • We present an unusual case of breast cancer with increased FDG uptake 4 months after chemotherapy.
  • A PET-CT scan displayed results that mimicked multiple lymph node metastases in the right axilla, the mediastinum, and the bilateral pulmonary hilar regions.
  • However, the increased FDG uptake disappeared 17 months later without any additional medical treatment, suggesting the occurrence of flare phenomenon.
  • [MeSH-major] Artifacts. Breast Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Lymph Nodes / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] False Positive Reactions. Female. Humans. Lymphatic Metastasis. Middle Aged. Radiopharmaceuticals / pharmacokinetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19857808.001).
  • [ISSN] 1873-4499
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


7. Akagi S, Ozaki S, Kishimoto T: [A case of splenic hemorrhage in the course of malignant mesothelioma]. Nihon Kokyuki Gakkai Zasshi; 2004 Mar;42(3):253-6
MedlinePlus Health Information. consumer health - Spleen Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of splenic hemorrhage in the course of malignant mesothelioma].
  • A 56-year-old man was admitted to our hospital because of mass lesions at the levels of the right upper and lower lung regions on a chest plain radiograph.
  • Chest computed tomography showed tumors which projected from the pleura of the right upper and lower lung fields.
  • Malignant mesothelioma was diagnosed by biopsy of the pleura via echogram.
  • Both chemotherapy and radiotherapy were administered because of brain metastasis and direct rib invasion.
  • Under this combined therapy, sudden anemia and hypotension appeared due to splenic hemorrhage, which suggested splenic metastasis of the malignant mesothelioma.
  • Multiple metastases in, for example, the spleen, brain, lung, liver, duodenum, small intestine, kidney, adrenal gland, vertebra, thyroid gland, and lymph nodes were confirmed by autopsy.
  • Distant metastasis is rare for malignant mesothelioma, and we report here a case of splenic metastasis with splenic hemorrhage in malignant mesothelioma.
  • [MeSH-major] Hemorrhage / etiology. Mesothelioma / secondary. Pleural Neoplasms / pathology. Splenic Diseases / etiology. Splenic Neoplasms / secondary
  • [MeSH-minor] Brain Neoplasms / secondary. Fatal Outcome. Humans. Lung Neoplasms / secondary. Male. Middle Aged

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15069782.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Kong FM, Ten Haken RK, Schipper MJ, Sullivan MA, Chen M, Lopez C, Kalemkerian GP, Hayman JA: High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys; 2005 Oct 1;63(2):324-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study.
  • PURPOSE: To determine whether high-dose radiation leads to improved outcomes in patients with non-small-cell lung cancer (NSCLC).
  • METHODS AND MATERIALS: This analysis included 106 patients with newly diagnosed or recurrent Stages I-III NSCLC, treated with 63-103 Gy in 2.1-Gy fractions, using three-dimensional conformal radiation therapy (3D-CRT) per a dose escalation trial.
  • Targets included the primary tumor and any lymph nodes > or =1 cm, without intentionally including negative nodal regions.
  • Nineteen percent of patients (20/106) received neoadjuvant chemotherapy.
  • Patient, tumor, and treatment factors were evaluated for association with outcomes.
  • The 5-year OS was 4%, 22%, and 28% for patients receiving 63-69, 74-84, and 92-103 Gy, respectively.
  • Although presence of nodal disease was negatively associated with locoregional control under univariate analysis, radiation dose was the only significant predictor when multiple variables were included (p = 0.015).
  • The 5-year control rate was 12%, 35%, and 49% for 63-69, 74-84, and 92-103 Gy, respectively.
  • CONCLUSIONS: Higher dose radiation is associated with improved outcomes in patients with NSCLC treated in the range of 63-103 Gy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Combined Modality Therapy. Disease-Free Survival. Dose Fractionation. Female. Humans. Male. Middle Aged. Prospective Studies. Radiotherapy Dosage. Survival Rate


9. Semrau S, Bier A, Thierbach U, Virchow C, Ketterer P, Fietkau R: Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results. Strahlenther Onkol; 2003 Dec;179(12):823-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
  • BACKGROUND: In elderly patients, patients with multiple morbidities, and patients with a reduced general condition, the standard treatment of inoperable non-small-cell lung cancer (NSCLC) consists of either chemotherapy or radiation therapy alone and is associated with an extremely poor prognosis.
  • We therefore investigated the feasibility, toxicity, and efficacy of radiotherapy with concurrent chemotherapy using vinorelbine plus cisplatin or carboplatin in NSCLC patients at risk for treatment complications.
  • PATIENTS AND METHODS: A total of 33 patients (six women, 27 men, median age 65 years) with locally advanced, functionally inoperable pulmonary carcinomas, recurrent lung cancer or postoperative macroscopic residual tumors (R2) with an increased risk of treatment complications (WHO performance status 2/3; cardiac, renal or pulmonary failure; marked pretherapeutic weight loss; age between 71-75 years) received 12.5 mg of vinorelbine per m(2) body surface area (BSA) on days 1, 8, 15, 29, 36 and 43 plus either cisplatin 20 mg/m(2) BSA (ten patients) or carboplatin 70 mg/m(2) BSA (23 patients) on days 1-5 and 29-33 together with conventionally fractionated radiotherapy.
  • The tumor regions were irradiated with doses of up to 63 Gy (90% isodose), and potentially affected lymph nodes received doses of up to 45.0 or 50.4 Gy (90% isodose).
  • RESULTS: Briefly, 31 of 33 patients successfully completed radiation therapy and 26 received four cycles of vinorelbine plus at least two cycles of cisplatin or carboplatin.
  • The survival rates plus standard deviations were as follows: 1-year survival: 60 +/- 8%, 2-year survival: 36 +/- 9%, 3-year survival: 24 +/- 9%, median survival time: 17 months (5;29 months; 95% confidence interval [CI]), median progression-free survival: 11 months (9;13 months; 95% CI).
  • The median follow-up time was 14 months.
  • CONCLUSION: Conventionally fractionated radiochemotherapy with vinorelbine plus a platinum derivative is feasible in patients with NSCLC and increased risk of treatment complications.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Cisplatin / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Vinblastine / analogs & derivatives. Vinblastine / therapeutic use
  • [MeSH-minor] Adult. Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Carboplatin / therapeutic use. Combined Modality Therapy. Confidence Intervals. Dose Fractionation. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Particle Accelerators. Radiography, Thoracic. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Risk Factors. Survival Analysis. Time Factors. Tomography, X-Ray Computed. World Health Organization

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14652671.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


10. Coburn NG, Guller U, Baxter NN, Kiss A, Ringash J, Swallow CJ, Law CH: Adjuvant therapy for resected gastric cancer--rapid, yet incomplete adoption following results of intergroup 0116 trial. Int J Radiat Oncol Biol Phys; 2008 Mar 15;70(4):1073-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy for resected gastric cancer--rapid, yet incomplete adoption following results of intergroup 0116 trial.
  • This study examined the adoption of adjuvant treatment following the trial results and the factors associated with its use.
  • A greater depth of tumor invasion, worse nodal status, and more lymph nodes assessed were associated with adjuvant RT (p<0.0001).
  • The rate of adjuvant RT varied from 22.9-44.2% across SEER regions.
  • On multiple logistic regression analysis, age, SEER region, marital status, assessed lymph nodes, tumor depth, and nodal status were all significant independent predictors of the use of adjuvant RT.
  • Additional examination of the statistically significant and clinically relevant variability between different SEER regions, tumor characteristics, and patient demographics is warranted.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Analysis of Variance. Chemotherapy, Adjuvant / utilization. Chi-Square Distribution. Clinical Trials, Phase III as Topic. Female. Humans. Male. Marital Status. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant / utilization. Randomized Controlled Trials as Topic. SEER Program. Sex Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17905529.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Pendlebury SC, Ivanov O, Renwick S, Stevens GN: Long-term review of a breast conservation series and patterns of care over 18 years. ANZ J Surg; 2003 Aug;73(8):577-83
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term review of a breast conservation series and patterns of care over 18 years.
  • BACKGROUND: Multiple randomized trials of breast conservation compared with mastectomy in early breast cancer have validated equivalence of survival.
  • Overwhelmingly the standard management of breast conservation includes surgical removal of the tumour, axillary dissection, postoperative breast irradiation, and adjuvant systemic therapy as appropriate.
  • The outcomes are reviewed of 832 women with early breast cancer treated by local resection and irradiation at Royal Prince Alfred Hospital over an 18 year period, with particular emphasis on the changing patterns of practice.
  • METHODS: Between September 1978 and May 1996, 832 women with early stage breast cancer were treated with conservative surgery and radiation therapy.
  • The changes in patient, tumour and treatment factors were analysed over this time period.
  • Half of the local recurrences were at the primary site.
  • Actuarial 5 year local recurrence (4%, 6%, 2%) and survival (96%, 88%, 92%) rates varied little across the three time intervals.
  • There was an increase in median age from 46 to 56 years over the accrual period, with no change in median primary tumour size (1.5 cm).
  • Surgically, the median number of axillary lymph nodes retrieved (14) did not alter significantly.
  • With respect to adjuvant therapies, irradiation of lymph nodes regions decreased over time.
  • The proportion of patients receiving adjuvant hormones or chemotherapy increased significantly (18%, 35%, 54%).
  • CONCLUSIONS: The low local recurrence rate and high survival are consistent with published literature for early breast cancer.
  • Changes in practice during the accrual period included improvements in histopathological reporting, a reduction in irradiation of lymph node regions, and an increase in the use of systemic therapy.
  • These changes parallel international recommendations regarding the optimal management of early breast cancer.
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / therapy. Mastectomy, Segmental / statistics & numerical data. Neoplasm Recurrence, Local / epidemiology. Professional Practice / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy / statistics & numerical data. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12887521.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


12. McMeekin DS, Tillmanns T: Endometrial cancer: treatment of nodal metastases. Curr Treat Options Oncol; 2003 Apr;4(2):121-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial cancer: treatment of nodal metastases.
  • Surgical staging has changed the method by which patients with endometrial cancer are managed.
  • Before the routine use of lymph node dissection, patients were presumed to have nodal disease based on imaging studies, palpation, and biopsy.
  • The move to a surgically based staging system in 1988 created a new subgroup of patients who had documented nodal disease.
  • Although patients with nodal disease are uncommon, treatment of these patients poses multiple challenges.
  • It is our belief that unless nodes are surgically assessed, the clinician will not know whether the nodes are involved.
  • A thorough lymphadenectomy with removal of nodal tissue from multiple pelvic sites and from bilateral para-aortic regions is recommended for most patients with endometrial cancer.
  • Identification of positive nodes allows appropriate postoperative therapies to be used, and data support that nodal dissection may be therapeutic and prognostic.
  • Patients with positive nodes should receive radiation therapy directed to the nodal distribution, with patients having involved para-aortic nodes receiving an extended field.
  • The most promising treatment option is combination therapy with sequential radiation and chemotherapy.
  • Active chemotherapy agents in endometrial cancer are doxorubicin, cisplatin, and paclitaxel.
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Hysterectomy. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Staging

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Oct;83(1):1-5 [11585406.001]
  • [Cites] Gynecol Oncol. 1991 Jan;40(1):55-65 [1989916.001]
  • [Cites] Gynecol Oncol. 1994 Oct;55(1):47-50 [7959265.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):348-56 [10684709.001]
  • [Cites] Gynecol Oncol. 1999 Nov;75(2):211-4 [10525373.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):273-8 [11330962.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(2):223-7 [1526859.001]
  • [Cites] Cancer. 1987 Oct 15;60(8 Suppl):2035-41 [3652025.001]
  • [Cites] Am J Obstet Gynecol. 1994 Jun;170(6):1677-81; discussion 1681-2 [8203425.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Gynecol Oncol. 2002 Feb;84(2):194-200 [11812074.001]
  • [Cites] Br J Cancer. 1997;75(12):1836-41 [9192991.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):4-9 [10502417.001]
  • [Cites] Gynecol Oncol. 1995 Jan;56(1):29-33 [7821843.001]
  • [Cites] Gynecol Oncol. 1995 Aug;58(2):189-93 [7622103.001]
  • [Cites] Gynecol Oncol. 1990 Feb;36(2):166-71 [2298404.001]
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):498-503 [11520146.001]
  • (PMID = 12594938.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


13. Du C, Bright JJ, Sriram S: Inhibition of CD40 signaling pathway by tyrphostin A1 reduces secretion of IL-12 in macrophage, Th1 cell development and experimental allergic encephalomyelitis in SJL/J mice. J Neuroimmunol; 2001 Mar 1;114(1-2):69-79
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vivo therapy with A1 leads to decrease in generation of myelin basic protein (MBP) specific encephalitogenic T cells.
  • In addition, treatment of SJL/J mice with A1 results in attenuation of experimental allergic encephalomyelitis (EAE).
  • [MeSH-minor] Animals. Autoantigens / immunology. CD40 Ligand / pharmacology. Cell Division / immunology. Cell Nucleus / metabolism. Cells, Cultured. Female. Gene Expression / drug effects. Gene Expression / immunology. Interferon-gamma / metabolism. Lymph Nodes / cytology. Mice. Mice, Inbred Strains. Myelin Basic Protein / immunology. NF-kappa B / genetics. NF-kappa B / metabolism. Promoter Regions, Genetic / immunology. Solubility

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11240017.001).
  • [ISSN] 0165-5728
  • [Journal-full-title] Journal of neuroimmunology
  • [ISO-abbreviation] J. Neuroimmunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / Autoantigens; 0 / Myelin Basic Protein; 0 / NF-kappa B; 0 / Tyrphostins; 147205-72-9 / CD40 Ligand; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


14. Oguz Y, Yilmaz MI, Eyileten T, Caglar K, Yenicesu M, Kaya A, Tasar M, Saglam M, Doganci L, Gulec B, Oner K, Oktenli C, Vural A: Persistent mediastinal and axillary lymph node tuberculosis in a renal transplant patient with successful outcome. Transplant Proc; 2006 Jun;38(5):1336-40
MedlinePlus Health Information. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent mediastinal and axillary lymph node tuberculosis in a renal transplant patient with successful outcome.
  • We report here about a 21 year-old man with a living related renal transplant from his mother who developed persistent extra-pulmonary tuberculosis.
  • The disease showed aggressive invasion to the axillary and mediastinal regions with abscess formations, despite standard antituberculosis treatment.
  • During the course of the disease, immunosuppressive therapy was stopped, and the patient received extraordinary doses of multiple antituberculosis drugs.
  • [MeSH-major] Antitubercular Agents / therapeutic use. Immunosuppression / methods. Kidney Transplantation / immunology. Lymphatic Diseases / microbiology. Mediastinal Diseases / microbiology. Tuberculosis / pathology
  • [MeSH-minor] Adult. Drug Administration Schedule. Humans. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / therapeutic use. Lymph Nodes / microbiology. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16797296.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antitubercular Agents; 0 / Immunosuppressive Agents
  •  go-up   go-down


15. Ross TM, Martinez PM, Renner JC, Thorne RG, Hanson LR, Frey WH 2nd: Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol; 2004 Jun;151(1-2):66-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis.
  • Intranasal administration resulted in significant delivery throughout the CNS and cervical lymph nodes with low delivery to peripheral organs.
  • Intranasal administration offers a non-invasive method of drug delivery for multiple sclerosis (MS) that bypasses the blood-brain barrier (BBB) and directly targets the CNS and lymph nodes.
  • [MeSH-major] Blood-Brain Barrier / physiology. Central Nervous System / chemistry. Immunosuppressive Agents / administration & dosage. Interferon-beta / administration & dosage. Multiple Sclerosis / drug therapy
  • [MeSH-minor] Administration, Intranasal. Animals. Autoradiography. Blotting, Western. Brain Chemistry. Cervical Vertebrae. Injections, Intravenous. Lymph Nodes. Male. Rats. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15145605.001).
  • [ISSN] 0165-5728
  • [Journal-full-title] Journal of neuroimmunology
  • [ISO-abbreviation] J. Neuroimmunol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 77238-31-4 / Interferon-beta
  •  go-up   go-down


16. Prayson RA, Sebek BA: Parotid gland malignant melanomas. Arch Pathol Lab Med; 2000 Dec;124(12):1780-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid gland malignant melanomas.
  • BACKGROUND: Malignant melanomas are relatively unusual tumors in the parotid gland.
  • The majority of previously reported cases appear to represent metastatic lesions, often from cutaneous head and neck primaries.
  • METHODS: Retrospective clinicopathologic review of 12 cases of malignant melanoma involving the parotid gland encountered between 1980 and October 1999 at a tertiary referral center.
  • Eleven of 12 patients presented with a neck mass or nodule.
  • In 2 patients, a cutaneous melanoma and the parotid gland melanoma were diagnosed at the same time.
  • In 1 patient, melanoma was initially diagnosed in the parotid gland, and a definite primary was not uncovered.
  • All patients underwent excision of the parotid melanoma, which was accompanied by a lymph node biopsy or dissection in 10 out of 11 patients.
  • Four patients received adjuvant radiotherapy, and 3 patients received adjuvant chemotherapy.
  • Four of 11 patients had ipsilateral cervical lymph node metastasis at the time of parotid tumor resection, and 5 patients had involvement of intraparotid lymph nodes by metastatic melanoma.
  • Tumors ranged in size from 0.3 to 2.5 cm in greatest dimension.
  • Multiple parotid nodules were noted in 4 patients.
  • Four tumors demonstrated focal spindle cell regions.
  • CONCLUSIONS: The majority of melanomas involving the parotid gland appeared to be associated with lymph node metastasis in and around the gland from a cutaneous primary in the head region.
  • Prognosis is generally poor, although rare patients may survive a long period of time following surgery.
  • [MeSH-major] Melanoma / pathology. Parotid Neoplasms / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Parotid Gland / pathology. Parotid Gland / surgery. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11100057.001).
  • [ISSN] 0003-9985
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down






Advertisement